Two posters presented at the CHEST Annual Meeting 2023 showed how real-world exacerbation rates in asthma and chronic obstructive pulmonary disease (COPD) dropped after patients started using a single ...

The maintenance inhalers available for obstructive lung disease are long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICSs). We use all three ...

Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA? Treatment with once-daily single-inhaler fluticasone ...

There is not enough evidence that manual therapy—a clinical approach of using skilled, physical, hands-on procedures to improve function, lessen pain, and facilitate movement—can ...

The American College of Chest Physicians ® (CHEST) announced the publication of updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension (PAH). PAH is a progressive ...

COPD, lung x ray The adjusted rate of decline in predose trough FEV1 during 52 weeks in the Researchers used a substudy of the Phase 3 ETHOS study to evaluate lung function decline in patients with ...

Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Please provide your email address to receive an email when new articles are posted on . Perioperative combination therapy using a long-acting muscarinic antagonist and long-acting beta agonist may be ...

If you have chronic obstructive pulmonary disease (COPD), your airways may be inflamed. It may be hard to take deep breaths and get enough oxygen. Depending on the severity of your COPD, oxygen ...

Select your location to view local American Lung Association events and news near you.